ArticlePloS one2016
Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Pooled it
- Prostate cancer risk SNP rs10993994 is a trans-eQTL for SNHG11 mediated through MSMB.Human molecular genetics · 2020Pooled it
- Pooled it
- Inter-Eye Molecular Discrepancies in the Corneal Epithelium Point to TFRC in the Keratoconus Severity Signature and Mechanism of Cone Formation.Investigative ophthalmology & visual science · 2025Article
- Construction of a prostate adenocarcinoma molecular classification: integrating spatial transcriptomics with retrospective cohort validation.Journal of translational medicine · 2025Article
- SPOT: spatial proteomics through on-site tissue-protein-labeling.Clinical proteomics · 2024Article
- Article
- Review
- Suggesting Tissue-Specific MSMB Gene Promoter as a Novel Approach for Prostate Targeted Gene Therapy.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- miR-32 promotes MYC-driven prostate cancer.Oncogenesis · 2022Article
- LMTK2 as Potential Biomarker for Stratification between Clinically Insignificant and Clinically Significant Prostate Cancer.Journal of oncology · 2021Article
- The Unsupervised Feature Selection Algorithms Based on Standard Deviation and Cosine Similarity for Genomic Data Analysis.Frontiers in genetics · 2021Article
- The Ubiquitin-Proteasome System Does Not Regulate the Degradation of Porcine β-Microseminoprotein during Sperm Capacitation.International journal of molecular sciences · 2020Article
- Overview of research on fusion genes in prostate cancer.Translational cancer research · 2020Review
- The role of plasma microseminoprotein-beta in prostate cancer: an observational nested case-control and Mendelian randomization study in the European prospective investigation into cancer and nutrition.Annals of oncology : official journal of the European Society for Medical Oncology · 2019Observational
- Contribution ofOncotarget · 2019Article
- Post-GWAS in prostate cancer: from genetic association to biological contribution.Nature reviews. Cancer · 2019Review
- Prostate Cancer Germline Variations and Implications for Screening and Treatment.Cold Spring Harbor perspectives in medicine · 2018Review
- Oxidative stress in prostate hyperplasia and carcinogenesis.Journal of experimental & clinical cancer research : CR · 2016Review
- Correction: Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer.PloS one · 2016Article
Corrections and comments
- Erratum issued
Authors and funding
13 authors at 4 institutions in 4 countries.
Funding
Abstract
Microseminoprotein-beta (MSMB, MSMB) is an abundant secretory protein contributed by the prostate, and is implicated as a prostate cancer (PC) biomarker based on observations of its lower expression in cancerous cells compared with benign prostate epithelium. However, as the current literature on MSMB is inconsistent, we assessed the expression of MSMB at the protein and mRNA levels in a comprehensive set of different clinical stages of PC. Immunohistochemistry using monoclonal and polyclonal antibodies against MSMB was used to study protein expression in tissue specimens representing prostatectomies (n = 261) and in diagnostic needle biopsies from patients treated with androgen deprivation therapy (ADT) (n = 100), and in locally recurrent castration-resistant PC (CRPC) (n = 105) and CRPC metastases (n = 113). The transcript levels of MSMB, nuclear receptor co-activator 4 (NCOA4) and MSMB-NCOA4 fusion were examined by qRT-PCR in prostatectomy samples and by RNA-sequencing in benign prostatic hyperplasia, PC, and CRPC samples. We also measured serum MSMB levels and genotyped the single nucleotide polymorphism rs10993994 using DNA from the blood of 369 PC patients and 903 controls. MSMB expression in PC (29% of prostatectomies and 21% of needle biopsies) was more frequent than in CRPC (9% of locally recurrent CRPCs and 9% of CRPC metastases) (p<0.0001). Detection of MSMB protein was inversely correlated with the Gleason score in prostatectomy specimens (p = 0.024). The read-through MSMB-NCOA4 transcript was detected at very low levels in PC. MSMB levels in serum were similar in cases of PC and controls but were significantly associated with PC risk when adjusted for age at diagnosis and levels of free or total PSA (p<0.001). Serum levels of MSMB in both PC patients and controls were significantly associated with the rs10993994 genotype (p<0.0001). In conclusion, decreased expression of MSMB parallels the clinical progression of PC and adjusted serum MSMB levels are associated with PC risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.